Livzon Pharmaceutical Group Inc. held its 2025 Annual General Meeting (AGM) alongside the 2026 First A-Share and H-Share Class Meetings on 29 May 2026 in Zhuhai, Guangdong. All resolutions on the agenda were approved by poll.
Robust Shareholder Participation • AGM turnout reached 49.20 % of issued share capital, representing 436.87 million shares (248.90 million A shares and 187.97 million H shares). • A-Share Class Meeting attendance equalled 42.32 % of A-share capital, while the H-Share meeting saw 62.70 % of H-share capital represented.
Key Ordinary Resolutions Passed • 2025 Annual Report and Results, Board Work Report and Financial Settlement Report each secured at least 99.88 % support. • Reappointment of Grant Thornton as 2026 auditor gained 95.54 % approval (4.44 % opposed). • 2025 profit distribution plan—cash dividend of RMB14.30 per 10 shares—was endorsed by 99.88 % of votes. • Director remuneration plan for 2026 passed with 97.13 % support after related parties holding 318.23 million shares abstained. • Director remuneration policy and guarantee mandates all exceeded the 99 % approval threshold.
Special Resolutions and Mandates • Amendments to the Articles of Association received 99.93 % affirmative votes. • A general mandate allowing the Board to repurchase H shares was approved in both the AGM (99.74 % support), the A-Share Class Meeting (99.76 %) and the H-Share Class Meeting (99.72 %).
Board Composition Confirmed via Cumulative Voting • Re-elections of non-independent directors Mr Zhu Baoguo, Mr Tang Yanggang, Mr Lin Nanqi and Mr Qiu Qingfeng each attracted support above 97 %. • Independent directors Mr Luo Huiyuan, Ms Cui Lijie and Ms Wang Zhiyao were re-elected with at least 99.16 % backing. • New appointments of Mr Liu Daping (executive director) and Ms Kang Li (independent non-executive director) received 99.01 % and 99.44 % support, respectively.
Dividend Details • Cash dividend: RMB14.30 (tax inclusive) per 10 shares. • Record date: 17 June 2026; payment to H-shareholders by 13 July 2026. • H-share dividend to be paid in Hong Kong dollars at HKD1 = RMB0.8703, equivalent to approximately HKD16.43 per 10 shares. • The company will withhold 10 % enterprise income tax on dividends to non-resident corporate H-shareholders; individual H-shareholders remain exempt under prevailing PRC tax regulations.
Corporate Governance and Compliance All directors attended the meetings in person or via electronic means. Guangdong Chongli Law Firm confirmed that meeting procedures, participant qualifications and voting processes complied with PRC laws, regulations and the Articles of Association, validating all resolutions.
The strong shareholder endorsement across ordinary, special and cumulative voting items reinforces confidence in Livzon Pharmaceutical’s strategic direction and governance framework as it enters its 12th Board session.
Comments